Suivre
Aaron Kesselheim
Aaron Kesselheim
Professor of Medicine, Harvard Medical School & Brigham and Women's Hospital
Adresse e-mail validée de partners.org - Page d'accueil
Titre
Citée par
Citée par
Année
False negative tests for SARS-CoV-2 infection—challenges and implications
S Woloshin, N Patel, AS Kesselheim
New England Journal of Medicine 383 (6), e38, 2020
8102020
Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis
AS Kesselheim, AS Misono, JL Lee, MR Stedman, MA Brookhart, ...
Jama 300 (21), 2514-2526, 2008
6502008
The high cost of prescription drugs in the United States: origins and prospects for reform
AS Kesselheim, J Avorn, A Sarpatwari
Jama 316 (8), 858-871, 2016
5652016
Regulation of medical devices in the United States and European Union
DB Kramer, S Xu, AS Kesselheim
New England journal of medicine 366 (9), 848-855, 2012
2962012
FDA regulation of mobile health technologies
N Cortez, IG Cohen, AS Kesselheim
2822014
Failure of investigational drugs in late-stage clinical development and publication of trial results
TJ Hwang, D Carpenter, JC Lauffenburger, B Wang, JM Franklin, ...
JAMA internal medicine 176 (12), 1826-1833, 2016
2762016
Clinical decision support systems could be modified to reduce ‘alert fatigue’while still minimizing the risk of litigation
AS Kesselheim, K Cresswell, S Phansalkar, DW Bates, A Sheikh
Health affairs 30 (12), 2310-2317, 2011
2642011
Seizure outcomes following the use of generic versus brand-name antiepileptic drugs
AS Kesselheim, MR Stedman, EJ Bubrick, JJ Gagne, AS Misono, JL Lee, ...
Drugs 70 (5), 605-621, 2010
2472010
Contrast-induced nephropathy: how it develops, how to prevent it
MR Rudnick, A Kesselheim, S Goldfarb
Cleveland Clinic journal of medicine 73 (1), 75, 2006
2462006
Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer
AS Kesselheim, JA Myers, J Avorn
Jama 305 (22), 2320-2326, 2011
2382011
Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts
JS Yeh, JM Franklin, J Avorn, J Landon, AS Kesselheim
JAMA internal medicine 176 (6), 763-768, 2016
1962016
A randomized study of how physicians interpret research funding disclosures
AS Kesselheim, CT Robertson, JA Myers, SL Rose, V Gillet, KM Ross, ...
New England Journal of Medicine 367 (12), 1119-1127, 2012
1952012
Electronic medication packaging devices and medication adherence: a systematic review
KD Checchi, KF Huybrechts, J Avorn, AS Kesselheim
Jama 312 (12), 1237-1247, 2014
1902014
Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study
JJ Gagne, NK Choudhry, AS Kesselheim, JM Polinski, D Hutchins, ...
Annals of internal medicine 161 (6), 400-407, 2014
1842014
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
AS Kesselheim, B Wang, JM Franklin, JJ Darrow
Bmj 351, 2015
1792015
Assessment of the clinical benefit of cancer drugs receiving accelerated approval
B Gyawali, SP Hey, AS Kesselheim
JAMA Internal Medicine 179 (7), 906-913, 2019
1762019
FDA approval and regulation of pharmaceuticals, 1983-2018
JJ Darrow, J Avorn, AS Kesselheim
Jama 323 (2), 164-176, 2020
1702020
Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review
KE Austad, J Avorn, AS Kesselheim
PLoS medicine 8 (5), e1001037, 2011
1652011
Innovative research methods for studying treatments for rare diseases: methodological review
JJ Gagne, L Thompson, K O’Keefe, AS Kesselheim
Bmj 349, 2014
1602014
Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration
H Naci, KR Smalley, AS Kesselheim
Jama 318 (7), 626-636, 2017
1492017
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20